



RECEIVED

JUL 23 2003

TECH CENTER PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: STEVENS, Fred J. et. al.
Title: "FIBRIL-BLOCKING PEPTIDE, A METHOD FOR PREVENTING FIBRIL FORMATION"
Serial No.: 09/712,819
Filing Date: November 13, 2000
Examiner: Dr. Phuong N. Huynh, Ph. D.
Art Unit: 1644

Attny Docket: 0003/00537

CERTIFICATE OF MAILING: I hereby certify that this correspondence is being deposited per 37 C.F.R. 1.8 with the United States Postal service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C., 20231 on July 17, 2003 (Date of Deposit).

Jillian Szafranski
Name of Representative

Jillian Szafranski
Signature

7/17/2003
Date of Signature

Commissioner for Patents
Alexandria, VA 22313

20 N. Wacker Drive
Chicago, IL 60606
312-621-1330

AMENDMENT REMARKS

Sir:

In response to the July 2, 2003 Notice to Comply with the Sequence Rules in the above-identified matter, applicant requests entry of the enclosed amended specification -section and claims. For sake of convenience to the Examiner, this AMENDMENT REMARKS section provides "marked-up" claims and the section of the specification to be amended.

Separate sheets, entitled "Amendment to Claims" and "Amendment to Specification," are attached hereto.

IN THE SPECIFICATION

Please amend the specification as follows:

On page 15, line 9, after "FTLTISS" insert --(SEQ ID NO: 1)--;
line 13, after "FTLTISS" insert --(SEQ ID NO: 1)--.

IN THE CLAIMS:

Please amend claim 13 as follows:

13. (Three Times Amended) The method as recited in claim 1 wherein the peptide interacts with endoplasmic reticulum chaperone, the peptide selected from the group consisting of TDFTLTI (SEQ ID NO: 5), FTLTISS (SEQ ID NO: 1), FTLKISR (SEQ ID NO: 6), FTLEISR (SEQ ID NO: [11] 12), and LTLKLSR (SEQ ID NO: [12] 13).

REMARKS

The application fails to comply with the requirements of 37 CFR 1.821 through 1.825. The computer readable form has been amended to conform to the correct paper copy. No new matter has been added.

The disclosure is objected to because of the requirement for SEQ ID NOS. for peptides on pages 3, 5-6, 8-10 and 15 of the specification. Please note that the SEQ ID NOS. required on pages 3, 5-6, and 8-10 of the specification were made in the amendment filed on March 25, 2001. The SEQ ID NOS. required on page 15 have been added as specified.

Claim 13 has been amended to indicate the correct SEQ ID NOS. for each peptide identified in the claim. The FTLEISR and LTLKLSR peptides were inadvertently misnumbered in the previous amendment.

Applicants submit that in light of the foregoing amendments and remarks thereto, the application is deemed in order for allowance.


An earnest attempt has been made hereby to respond to the informality objections contained in the July 2, 2003 official action. Applicants submit that the instant amendment places the application in condition for allowance. If the Examiner

In re STEVENS et al. (S.N. 09/712,819)
Response to July 2, 2003 Official Action
Page -3-

feels that a telephonic interview will expedite allowance of the Application, she is respectfully urged to contact the undersigned.

Respectfully submitted,

CHERSKOV & FLAYNIK

By 

Michael J. Cherskov (Reg. 33,664)